Final answer:
Detection of hepatic disorders and muscle dystrophies is achieved through blood tests, measuring liver enzymes and other biomarkers. Budd-Chiari syndrome, Gilbert's syndrome, and Glycogen storage disease type-II are various conditions affecting the liver and muscles. Elevated enzymes such as ALT, AST, ALP, GGT, and LDH provide insights into liver function and damage.
Step-by-step explanation:
To detect hepatic disorders, particularly intrahepatic disorders, and muscle dystrophies, various blood tests are necessary. Measures of liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), can indicate liver damage but are not specific to hepatic tissue. Other enzymes like alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (GGT) can help differentiate liver pathologies and the extent of liver function impairment.
In Budd-Chiari syndrome, the obstruction of the hepatic vein causes hepatic dysfunction. In contrast, Gilbert's syndrome is a genetic disorder of bilirubin metabolism, manifesting as jaundice. Glycogen storage disease type-II leads to the accumulation of glycogen in various tissues, resulting in muscle weakness and liver involvement.
Liver function tests, including measurements of blood levels of bilirubin, serum albumin, and total protein, as well as a complete metabolic panel (CMP), can provide initial indications of liver problems. For suspected hepatitis, a hepatitis virus serological test panel detects specific antibodies. Enzymes like lactate dehydrogenase (LDH) may be elevated due to liver damage and are a marker for cellular damage, including hemolysis and tissue injury in various organs.